Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de cabozantinibe e nivolumabe com radioterapia para pessoas com carcinoma de células renais que se espalhou para o cérebro

13 de novembro de 2026 atualizado por: Memorial Sloan Kettering Cancer Center

Estudo de fase 1b da segurança de cabozantinibe e nivolumabe concomitantes com radioterapia para metástases cerebrais em pacientes com carcinoma de células renais metastático

The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

2

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
      • Middletown, New Jersey, Estados Unidos, 07748
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
      • Montvale, New Jersey, Estados Unidos, 07645
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities)
      • Harrison, New York, Estados Unidos, 10604
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      • Uniondale, New York, Estados Unidos, 11553
        • Memorial Sloan Kettering Nassau (All Protocol Activities)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Unresectable advanced or metastatic clear cell or non-clear cell RCC; all histologies acceptable except for chromophobe RCC

  2. Brain metastases present, meeting the following criteria:

    1. At least 1 brain metastasis measuring ≥0.5cm in any dimension (intracranial RANO-BM measurable disease required)
    2. SRS is indicated per treating radiation oncologist
    3. Surgical intervention for brain metastases is not planned
  3. Able to undergo MRI Brain assessments for radiation planning.

  4. Availability of archival tissue that enables the definitive diagnosis of RCC, accompanied by an associated pathology report. If archival tissue cannot be obtained, PI to provide documented confirmation patient can still enroll onto the study. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion.

  5. Age ≥18 years

  6. KPS ≥ 80

  7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:

    1. ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)
    2. WBC counts ≥ 2500/μL
    3. Absolute lymphocyte count ≥ 500/μL
    4. Platelet count ≥100,000/μL (without transfusion within 4 weeks prior to Cycle 1, Day 1)
    5. Hemoglobin ≥9.0 g/dL o Patients may be transfused or receive erythropoietic treatment to meet this criterion.
  8. AST, ALT, and alkaline phosphatase ≤ 2.5 x ULN, with the following exceptions:

    1. Patients with documented liver metastases: AST and/or ALT ≤ 5 x ULN
    2. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 x ULN
  9. Serum bilirubin ≤ 1.5 x ULN

  10. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be- enrolled.

  11. INR and aPTT ≤ 1.5 x ULN

    a. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.

  12. Creatinine ≤ 1.5 x ULN or Calculated Creatinine clearance ≥ 30mL/min by institutional standard measurement

  13. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of ≥ 1% per year

  14. If any Grade ≥1 toxicities occurred in relation to prior treatment, patients must have recovered to baseline or ≤ Grade 1 unless adverse events are clinically insignificant or stable on supportive medication if needed.

Exclusion Criteria:

  1. Prior treatment with cabozantinib for RCC

  2. Receipt of any small molecule kinase inhibitor (including investigational) or VEGFtargeted therapy within 2 weeks before the first dose of study treatment

    o 2-week washout period was selected in order to facilitate rapid enrollment and treatment of patients given the target population with active brain metastases.

  3. Patients requiring whole brain radiotherapy (WBRT).

  4. Any prior brain radiotherapy within 28 days prior to enrollment

  5. Incomplete healing from prior radiotherapy as determined by the treating radiation oncologist or treating investigator

  6. Diagnosis of autoimmune condition that may worsen during immune checkpoint blockade, with the following exceptions:

    o Diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

  7. Any active or suspected autoimmune disease requiring systemic steroids > 10 mg daily prednisone (or equivalent) or other immunosuppression, except for:

    • those not expected to reoccur
    • Chronic physiologic replacement of ≤10mg prednisone (or equivalent) for treatment of adrenal insufficiency
    • Steroids required for pre-medication reactions
    • Local steroid use is permitted (e.g. intranasal, topical, inhaled, or local steroid injection, i.e. intra-articular)
  8. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

  9. Uncontrolled hypercalcemia (≥ 1.5 mmol/L ionized calcium or Ca ≥ 12 mg/dL or corrected serum calcium ≥ ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab

  10. Participation in an experimental drug study within 28 days of study enrollment

  11. Pregnant and lactating women

  12. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  13. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina, or EF < 50%

    o Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  14. Uncontrolled hypertension (>140 mm Hg systolic or >90 mm Hg diastolic) despite optimal antihypertensive treatment

  15. QTcF > 500 msec within 28 days before the first dose of study treatment

  16. Major surgical procedure within 14 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study

    o Patients must have completed wound healing from major or minor surgery before first dose of study treatment

  17. History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1

  18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1

  19. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

    o Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of red blood or other history of significant bleeding within 12 weeks before first dose of study treatment.

  20. Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding

  21. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure

  22. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

  23. Concomitant anticoagulation with coumarin agents, direct thrombin inhibitors, factor Xa inhibitor betrixaban, or platelet inhibitors. Other anticoagulants are allowed.

  24. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.

    o Complete healing of intra-abdominal abscess must be confirmed before the first dose of study treatment

  25. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation

  26. Lesions invading or encasing major blood vessels

  27. Uncompensated or symptomatic hypothyroidism

  28. History of solid organ or allogeneic stem cell transplant

  29. Clinically significant active infection including HIV, Hepatitis B, Hepatitis C, acute COVID-19 infection, or other

    • For patients with HIV infection, clinically significant/exclusionary features include: detectable viral load, CD4+ T cell count <300 cells/microL, or history of opportunistic infection
    • For patients with HBV infection, clinically significant/exclusionary features include: HBV surface antigen positivity, detectable HBV DNA by polymerase chain reaction (PCR). Patients with prior HBV infection (HBV core Ab positive, HBV DNA undetectable by PCR, HBV surface antigen negative) are eligible for the study if they are already stable on entecavir or tenofovir
  30. Inability to swallow tablets

  31. Previously identified allergy or hypersensitivity to components of the treatment

  32. Malignancy that requires anti-cancer directed therapy within the last 3 years. Exceptions include those cancers that are considered cured by local therapy (e.g. Basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of breast, bladder, or cervix) or other cancers that have low malignant potential and do not require systemic therapy (e.g. Gleason grade <6 prostate adenocarcinoma)

  33. Patients in whom nivolumab treatment is not otherwise feasible (for example, for financial reasons)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cabozantinib and Nivolumab With Radiation Therapy

Patients being newly initiated on cabo/nivo will be started on with cabozantinib 40 mg PO daily and nivolumab 480 mg IV day Q4 weeks

o Dose de-escalation of cabozantinib for toxicity will be allowed per prespecified toxicity dose levels

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist. Standard institutional regimens such as 18-24 Gy in a single fraction, 24-27 Gy in three fractions, and 25-30 Gy in five fractions are permissible.

Cabozantinib (40 mg PO daily)

Nivolumab (480 mg IV Day 1)

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
percent of enrolled patients who are able to tolerate treatment
Prazo: 56-day

56-day safety monitoring period without unacceptable CNS toxicity. Unacceptable CNS toxicity is defined as any grade ≥3 treatment-emergent neurological disorder, per NCI CTCAE version 5.0 criteria

56-day

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
rate of CNS adverse events
Prazo: 1 year

CNS adverse events will be reported as a proportion of patients who experience a CNS adverse event of any grade based on CTCAE 5.0

1 year
objective response rate (ORR)
Prazo: 1 year

as measured by RANO-BM criteria

1 year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Ritesh Kotecha, MD, Memorial Sloan Kettering Cancer Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de novembro de 2023

Conclusão Primária (Estimado)

1 de novembro de 2027

Conclusão do estudo (Estimado)

1 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2023

Primeira postagem (Real)

15 de novembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever